NeoRx gets recommendation for Verluma:
This article was originally published in Clinica
The US FDA Oncologic Drugs Advisory Committee has recommended approval for Verluma, NeoRx' small cell lung cancer imaging agent. Verluma is an antibody-technetium conjugate. Cancer is staged by whole body gamma scan 14 to 17 hours after injection. A PLA was filed in March 1994 by the manufacturer, Boehringer Ingelheim, which also holds non-North American marketing rights, DuPont Merck holds exclusive marketing rights for North America. Verluma will be manufactured in Germany by Boehringer Ingelheim subsidiary Dr Karl Thomae. Between 40 and 45,000 cases of small cell lung cancer are diagnosed every year in the US. About 70% are classed as extensive.